cynata share purchase plan

Mesenchymal stem cells (MSCs) have huge therapeutic potential for numerous unmet medical needs. If research subjects withdraw from a study, we will keep the information about them that we have already obtained. Cynata Successfully Completes Share Purchase Plan: 08 May 2020: Ethics Approval to Commence Clinical Trial in COVID-19: 01 May 2020: Cleansing Notice: 01 May 2020: Appendix 2A: 30 Apr 2020: Share Purchase Plan Booklet: 24 Apr 2020: Cleansing Notice: 24 Apr 2020: Appendix 2A: 24 Apr 2020: Quarterly Activity Report & Appendix 4C: 22 Apr 2020 The SPP allows Eligible Shareholders the opportunity to subscribe for up to $30,000 worth of New Shares without paying brokerage or other transaction costs. Current share prices are available on the ASX website The Company listed on the Australian Securities Exchange in November 2013, following a reverse takeover of Eco Quest Ltd.The share registry is managed by Automic Registry Services. Not all plans are the same.

Typically, Cynata holds its AGM in mid November.We may use personally-identifiable information to conduct research to improve health and care.

Cynata Therapeutics.

What is the Dividend Policy? This means that we will use individuals’ data, collected in the course of a research study, in the ways needed to conduct and analyse the research study. To safeguard the rights of research subjects, we will use the minimum personally-identifiable information possible.If you have participated in a Cynata-sponsored research study, and you wish to raise a complaint on how we have handled your personal data, you can contact us at clinical@cynata.com, and we will investigate the matter.The Company does not currently have a dividend policy in place. To login and access your holding information, please go to: Company shares are traded on the ASX and can be bought or sold through a licensed stockbroker.

On behalf of the Board, I am pleased to offer you the opportunity to apply for New Shares in the Company under a share purchase plan. The Company does not currently have a dividend policy in place. However, please check with your stockbroker the markets that they participate in and make sure that Australia is one of them.

If you have participated in a Cynata-sponsored research study, and you wish to raise a complaint on how we have handled your personal data, you can contact us at clinical@cynata.com, and we will investigate the matter. When the plan closed on May 22, Cynata received commitments for approximately $10.66 million worth of shares.This share purchase plan follows the company's recent $3.55 million placement, which was announced in The company says it increased the plan's end goal so that existing shareholders would have an equal opportunity to access what was offered in the placement.Under this plan, eligible shareholders had the opportunity to subscribe for up to $30,000 worth of new shares at a price of 60 cents each.As the share purchase plan was heavily oversubscribed, participants will receive 44.8 per cent of shares they applied for, with refunds to be given around June 2.The shares are expected to be dispatched on June 2 and begin trading on the ASX on June 3.The $8.3 million raised from both the placement and share purchase plan will be used to fund and speed-up the company's ongoing product development as well as going towards working capital.Cynata is up a slight 1.49 per cent on the market and shares are trading for 68 cents each at 12:48 pm AEST.Cancer treatment company Prescient Therapeutics (PTX) is progressing its PTX-100 drug to the dosing next level in its phase one trials of theBotanix Pharmaceuticals (BOT) has begun the recruitment phase for its BTX 1801 antimicrobial clinical study, which is aiming to prevent surgical site infectionsBiotechnology company, Immutep (IMM) has been granted a new

Level 3, 62 Lygon Street, CARLTON, VIC 3053 AUSTRALIA

When the plan closed on May 22, Cynata received commitments for approximately $10.66 million worth of shares. Cynata is down a slight 5.36 per cent and shares are currently trading for 66.3 cents each Biotech company Cynata Therapeutics (CYP) has updated the market on its March quarterly activities. It is the Company’s intention to fully commercialise its Cymerus platform and to reinvest any future profits in order to grow the business. During the quarter, Cynata made further progress with its three Phase 2 clinical trial programs for treating osteoarthritis, critical limb ischaemia, and graft-versus-host disease. Alternatively, online trading platforms offer solutions for overseas investors to invest in international equities.The Company strictly adheres to its continuous disclosure obligations and updates its website at All annual reports and financial reports are available on our website through this linkThe Company’s end of financial year is the 30th of June.A limited company is required to hold its annual general meeting within five months of its financial year end. In view of the very high rate of acceptances the Company has resolved to vary

The rights of research subjects to access, change or move their information are limited, as we need to manage their information in specific ways in order for the research to be reliable and accurate.

Biotech company Cynata Therapeutics (CYP) has successfully completed its share purchase plan.Due to the high rate of acceptance, the end goal has increased from the original $2 million to $4.8 million.